Physician profile
Christine Yu
NPI 1447496807
$1,755.83
in general payments reported to CMS, 2019-2025
36 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $39.74 · 2021: $66.26 · 2022: $242 · 2023: $214 · 2024: $565 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $236.44 | 2021-2025 | Rayaldee |
| Abbvie INC. | $135.14 | 2019-2025 | |
| Novo Nordisk INC | $122.18 | 2023-2025 | Wegovy |
| Celgene Corporation | $102.09 | 2023-2024 | Zeposia |
| Amgen INC. | $98.49 | 2022-2025 | Repatha, Evenity, Prolia |
| Genzyme Corporation | $98.06 | 2023-2025 | |
| Janssen Biotech, INC. | $81.29 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.08 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $73.15 | 2024 | Resmetirom |
| Ferring Pharmaceuticals INC. | $63.62 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $52.12 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.06 | 2022-2024 | Jardiance |
| Capsovision, INC. | $46.55 | 2024 | Capsocam Plus |
| Travere Therapeutics, INC. | $42.18 | 2025 | |
| Lilly USA, LLC | $38.04 | 2024-2025 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.34 | 2019-2022 | |
| Sanofi Pasteur INC. | $32.61 | 2022 | |
| Ironwood Pharmaceuticals, INC | $31.05 | 2019-2021 | |
| Redhill Biopharma INC. | $25.93 | 2020-2022 | |
| Ardelyx, INC. | $23.67 | 2024 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $23.01 | 2022 | |
| Scpharmaceuticals INC. | $22.08 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $21.98 | 2024 | Arcalyst |
| Concordia Pharmaceuticals INC. | $21.76 | 2019 | |
| Celltrion USA INC. | $20.75 | 2025 | Vegzelma |
| Medtronic, INC. | $20.59 | 2024 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $19.94 | 2025 | Imcivree |
| Renalytix Ai, INC. | $18.36 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Qol Medical, LLC | $18.21 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.83 | 2025 | Ultomiris |
| Corcept Therapeutics | $17.17 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.82 | 2023 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $14.52 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.74 | 2024 | Edarbi |
| Gilead Sciences, INC. | $12.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.